All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Diverse Enrollment in Clinical Trials is Crucial to Address Disparities and Improve Cancer Care

May 4th 2022

Ruben A. Mesa, MD, discusses the different disparities that are known to affect cancer care and key efforts being made to address them.

ARO-HIF2 Lowers HIF2α Expression and Demonstrates Favorable Safety Profile in Clear Cell RCC

May 4th 2022

The investigational RNA interference therapy, ARO-HIF2, reduced levels of hypoxia inducible factor-2 alpha expression and had acceptable tolerability when used in patients with clear cell renal cell carcinoma, according to data from the phase 1b AROHIF21001 trial.

Third Dose of COVID-19 Vaccine Significantly Increases Immune Responses in Most Patients With Multiple Myeloma

May 4th 2022

Most immunocompromised people with multiple myeloma benefited from a third dose of COVID-19 vaccines. However, some people with multiple myeloma still remained vulnerable and may need a fourth dose or antibody treatments as restrictions lift and new variants emerge

FDA Grants Priority Review to Durvalumab/Chemo Combo for Locally Advanced or Metastatic Biliary Tract Cancer

May 4th 2022

The FDA has accepted a supplemental biologics license application and granted priority review to durvalumab in combination with standard gemcitabine and cisplatin for the treatment of patients with locally advanced or metastatic biliary tract cancer.

Nivolumab Plus Chemotherapy Moves Into Neoadjuvant Setting in NSCLC

May 4th 2022

Mark Awad, MD, PhD, discusses how the approval of nivolumab opens the door for the new regimen to become a backbone for future treatment strategies.

Pembrolizumab With or Without Chemo Has Increased Efficacy With Increasing PD-L1 Expression in HNSCC

May 4th 2022

Pembrolizumab with or without chemotherapy resulted in a numerically longer overall survival benefit vs cetuximab plus chemotherapy in patients with head and neck squamous cell carcinoma and a PD-L1 combined positive score (CPS) between 1 and 19, but did not improve survival in the subset with a PD-L1 CPS of less than 1.

Addition of Apalutamide to ADT Does Not Reduce HRQOL in Metastatic Castration-Sensitive Prostate Cancer

May 3rd 2022

The addition of apalutamide to androgen deprivation therapy was not found to significantly reduce health-related quality of life or increase patient-reported adverse effect burden.

Cabozantinib Approved in Europe for Second-Line Radioactive Iodine–Refractory Differentiated Thyroid Cancer

May 3rd 2022

The European Commission has approved the use of cabozantinib for use as a single agent in adult patients with locally advanced or metastatic differentiated thyroid carcinoma who are refractory or not eligible to receive radioactive iodine and who have progressed during or following previous systemic treatment.

Cilta-Cel Induces Impressive ORR in Relapsed/Refractory Multiple Myeloma

May 3rd 2022

Thomas Martin, MD, discusses updates from the CARTITUDE-1 trial, as well as the future of CARs and bispecific T cell engagers in multiple myeloma.

Tucatinib Plus T-DM1 Represents Another Potential Therapy in High-Risk HER2-Positive Breast Cancer

May 3rd 2022

Heather McArthur, MD, MPH, discusses key treatment developments in early-stage and metastatic HER2-positive breast cancer and triple-negative breast cancer, plus ongoing research at UT Southwestern Harold C. Simmons Comprehensive Cancer Center.

Molecular Treatment Is Able to Control Brain Metastasis of Different Tumors

May 3rd 2022

Mount Sinai researchers conducting clinical trials of a drug targeting a cancer gene found that it increased metastatic cancer patients’ survival and was able to work within the brain.

FDA Grants Priority Review to Darolutamide/Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

May 3rd 2022

The FDA has accepted a supplemental new drug application and granted priority review to darolutamide plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Second-Line Axi-Cel Offers a “Practice-Changing” Indication for LBCL

May 3rd 2022

Lori A. Leslie, MD, reviews how the approval of axicabtagene ciloleucel may impact or enhance current practice patterns for adult patients with large B-cell lymphoma.

The Future of Frontline CLL Treatment Hinges on Chemotherapy-Free Approaches

May 3rd 2022

Anthony Mato, MD, MSCE, discusses current data surrounding BTK inhibitors in chronic lymphocytic leukemia, the benefits of targeted therapies in this population, ways to begin addressing unmet needs, and the importance of improved clinical trial designs for varying patient populations.

FDA Issues Complete Response Letter to Toripalimab for Nasopharyngeal Carcinoma

May 2nd 2022

The FDA is seeking the approval of toripalimab plus gemcitabine and cisplatin in the frontline treatment of patients with advanced recurrent or metastatic nasopharyngeal carcinoma and for use as a monotherapy in the second-line and later treatment of those with recurrent or metastatic disease.

Very Low Dose Radiation Therapy Demonstrates Efficacy in Indolent Non-Hodgkin Lymphoma

May 2nd 2022

Although it is not considered to be a standard of care for patients with indolent non-Hodgkin lymphoma, very low dose radiation therapy was found to have efficacy in the palliative setting and to allow for retreatment to the same field when needed.

Addition of Ublituximab/Umbralisib to Ibrutinib Produces High uMRD Rate in CLL

May 2nd 2022

The time-limited combination of ublituximab and umbralisib plus ibrutinib resulted in an undetectable minimal residual disease rate of 77% in patients with chronic lymphocytic leukemia, according to findings from a phase 2 trial (NCT04016805)

Armstrong Highlights Outcomes of Final Survival Analysis of Enzalutamide Plus ADT in mHSPC

May 2nd 2022

Andrew J. Armstrong, MD, discusses the updated results and the clinical implications of the final survival analysis of the ARCHES trial, which he coauthored.

FDA Issues Complete Response Letter to Surufatinib for Advanced Neuroendocrine Tumors

May 2nd 2022

The FDA has issued a complete response letter to the new drug application seeking the approval of surufatinib for the treatment of patients with pancreatic and extra-pancreatic neuroendocrine tumors.

Dana-Farber Cancer Institute and Lifespan Renew Strategic Alliance Agreement

May 2nd 2022

Dana-Farber Cancer Institute and the Lifespan Cancer Institute have agreed to renew their strategic alliance to advance cancer treatment and research. Dana-Farber and the Lifespan Cancer Institute signed an initial agreement in 2017.